Pacific Biosciences has stepped up the fight for the sequencing market with the introduction of an instrument that is smaller, cheaper and higher throughput than the model it replaces.
As industry heavyweights develop innovative technologies for longer reads of the human genome, RainDance Technologies and Pacific Biosciences are joining forces for a new project aimed at de novo whole-genome assembly.
RainDance Technologies and Pacific Biosciences are teaming up for de novo whole genome assembly as RainDance chases its previously announced IPO.
Struggling gene sequencer Pacific Biosciences signed a diagnostics product-development deal with industry giant Roche worth as much as $75 million.
Struggling gene sequencer Pacific Biosciences saw its stock rocket upward in the wake of a diagnostics development deal with industry giant Roche that's worth as much as $75 million, closing at $5.98 on Sept. 25, a jump of more than 72.8%.
Roche's massive diagnostics division has signed on with yet another development partner: California's Pacific Biosciences, which focuses on gene sequencing. The pair will develop diagnostics products for clinical research.
In the biotech game, New York City doesn't hold a candle to Boston or San Francisco. But if anyone can change that perception, perhaps it's Eric Schadt, the chief scientist of Pacific Biosciences (
The math on sequencing's growing reach is pretty simple. In 2009, a few dozen genomes were sequenced. Last year the genes of some 1,700 people were sequenced. This year, analysts say the number will
Pacific Biosciences ($PACB) wants to offer users of its sequencing machine new cloud computing capabilities amid struggles to hit sales targets for its cutting edge system for quickly and cheaply...
Creating a company on the bleeding edge of a new technology can cut both ways. After the initial demand for its highly touted sequencing tech fell short of expectations, Menlo Park, CA-based Pacific